[ad_1]
LEXINGTON, mbad., March 31, 2019 / PRNewswire / – Cyteir Therapeutics, a leader in the discovery and development of novel biology-based treatments for DNA repair and synthetic lethality for the treatment of cancer and autoimmune diseases, announced presentation of promising new preclinical data for the company's flagship compound, CYT-0851. Data is shared this week at the American Association for Cancer Research (AACR) annual meeting in 2019 and suggests that the new RAD51 inhibitor may be active as monotherapy against B-cell lymphoma and multiple solid tumors , including pancreatic cancer. The data also show that CYT-0851 is potentially synergistic in combination with PARP inhibitors and can overcome resistance to PARP inhibitors. Cyteir plans to launch clinical trials with CYT-0851 in mid-2019.
The Cyteir platform is based on the groundbreaking discovery of a relationship between activation-induced cytidine deaminase (AID), a DNA-damaging enzyme, and the RAD51 protein, essential for repairing breakouts of l & # 39; DNA. Overexpression of AID causes significant DNA damage in a large number of patients with B-cell malignancies and many patients with solid tumors. Cyteir is developing selective compounds based on small molecules that, according to the company, inhibit RAD51. In preclinical models, thereby reducing the ability of diseased cells to self-repair, is damaged by their own damage to DNA and causes cell death, resulting in a therapeutic effect called "synthetic lethality" . Kevin Mills, Ph.D., co-founder and chief scientist of Cyteir, led the research that first identified the synthetic lethality relationship between RAD51 and AID.
"The data presented at this year's AACR meeting validate the mechanism of action underlying our new approach to synthetic lethality and confirm that we have identified a potent selective oral inhibitor that could potentially broadly target multiple cancers." with high levels of DNA damage caused by AID ", said Markus Renschler, M.D., President and Chief Executive Officer of Cyteir. "We are well on the way to filing an IND in the middle of the year and we are eager to see how this exciting new mechanism works in clinical trials to improve outcomes for patients. patients with advanced cancer. "
Three presentations at the AACR 2019 conference support the potential of CYT-0851 to provide a new, effective and targeted treatment option for a variety of hematologic cancers and solid tumors. The data presented by the company today demonstrate in vitro CYT-0851 is synergistic and may be active in combination with PARP inhibitors (Poster Section 14, Board 363/24). The researchers tested five PARP inhibitors, each badociated with CYT-0851 in several tumor-derived cell lines with varying levels of AID expression and PARP inhibitor sensitivity. The results suggest that CYT-0851 increases the synthetic lethal activity of PARP inhibitors and could re-sensitize resistant tumors to this clbad of treatment.
The data predicted tomorrow confirm – in preclinical models – the mechanism of action of CYT-0851 in AID-overexpressing cancers, demonstrating that the compound reduces RAD51 activity, reduces the levels of repair of DNA and increases the damage caused to cancer cell death (Poster Section 35, Board 2566/10).
Cyteir will present Wednesday data from a preclinical study evaluating the in vivo CYT-0851 activity in AID-overexpressing B-cell lymphoma and solid tumors, particularly pancreatic cancer (Poster Section 10, Board 4730/20). In this study, the oral administration of the compound in three models of pancreatic cancer xenografts derived from the patient led to significant antitumor activity.
About Cyteir Therapeutics
Cyteir Therapeutics is a leader in the discovery and development of new therapies based on the biology of DNA repair. This is the first company to date to adopt a "gain-of-function" approach for synthetic lethality in the treatment of cancer and autoimmune diseases, such as type 1 diabetes, systemic lupus erythematosus and multiple sclerosis. Unlike other approved synthetic lethality therapies (including PARP inhibitors), which are used to treat cancers with DNA mutations that result in loss of function of specific genes such as BRCA, Cyteir targets the disease gaining function in AID. An abnormal gain in AIDS function occurs in a wide range of cancers and autoimmune diseases, but not in healthy tissues. The main molecules of Cyteir were initially discovered using the company's drug discovery platform, which allows for the identification of primary cells with adjustable genetic constraints. Cyteir is supported by leading healthcare investors including Venrock, Lightstone Ventures, Osage University Partners, DROIA Oncology Ventures and Celgene. For more information, visit www.cyteir.com.
MEDIA CONTACT:
Michele Parisi
For Cyteir Therapeutics
925-429-1850
[email protected]
See the original content: http: //www.prnewswire.com/news-releases/cyteir-therapeutics-announces-new-data-demonstrating-lead-compound-cyt-0851-is-active-against-lymphomas-and-solid -solid-synergistic tumors with parp inhibitors-300821407.html
SOURCE Cyteir Therapeutic
Source link
